R 5280
Alternative Names: R-5280Latest Information Update: 05 Jul 2024
At a glance
- Originator Rise Therapeutics
- Class Antihyperglycaemics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Type 1 diabetes mellitus
Most Recent Events
- 05 Dec 2023 Phase-I clinical trials in Type 1 diabetes mellitus (In children, In adolescents) in USA (PO) (NCT06057454)